The current global market for vaccines that contain a pertussis component exceeds $5 billion per year. Within this market, approximately $1.4B in sales is attributable to adult and adolescent vaccines and $3.7B to the pediatric market.

Since approval in 2005, sales of adult and adolescent acellular pertussis vaccines have grown rapidly, with nearly $1.4B in sales in 2019. Sales for adult and adolescent pertussis vaccines, the first target indication for BPZE1, are expected to exceed $2B by 2024.

Copyright 2013-2024 ILiAD Biotechnologies